Sernova Corp (SEOVF)
0.2663
+0.04
(+18.09%)
USD |
OTCM |
May 31, 16:00
Sernova Enterprise Value: 69.20M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 69.20M |
| May 30, 2024 | 56.82M |
| May 29, 2024 | 56.82M |
| May 28, 2024 | 61.22M |
| May 24, 2024 | 58.18M |
| May 23, 2024 | 52.27M |
| May 22, 2024 | 54.33M |
| May 21, 2024 | 53.81M |
| May 20, 2024 | 60.06M |
| May 17, 2024 | 59.70M |
| May 16, 2024 | 62.48M |
| May 15, 2024 | 65.86M |
| May 14, 2024 | 59.40M |
| May 13, 2024 | 66.43M |
| May 10, 2024 | 69.23M |
| May 09, 2024 | 73.46M |
| May 08, 2024 | 73.46M |
| May 07, 2024 | 75.69M |
| May 06, 2024 | 73.34M |
| May 03, 2024 | 73.35M |
| May 02, 2024 | 78.81M |
| May 01, 2024 | 77.11M |
| April 30, 2024 | 81.95M |
| April 29, 2024 | 88.26M |
| April 26, 2024 | 85.03M |
| Date | Value |
|---|---|
| April 25, 2024 | 82.32M |
| April 24, 2024 | 84.84M |
| April 23, 2024 | 87.05M |
| April 22, 2024 | 88.61M |
| April 19, 2024 | 88.19M |
| April 18, 2024 | 88.37M |
| April 17, 2024 | 88.04M |
| April 16, 2024 | 92.28M |
| April 15, 2024 | 91.64M |
| April 12, 2024 | 90.04M |
| April 11, 2024 | 103.69M |
| April 10, 2024 | 75.63M |
| April 09, 2024 | 76.69M |
| April 08, 2024 | 94.41M |
| April 05, 2024 | 99.11M |
| April 04, 2024 | 106.12M |
| April 03, 2024 | 109.70M |
| April 02, 2024 | 111.28M |
| April 01, 2024 | 114.87M |
| March 28, 2024 | 113.16M |
| March 27, 2024 | 112.92M |
| March 26, 2024 | 113.13M |
| March 25, 2024 | 116.65M |
| March 22, 2024 | 116.59M |
| March 21, 2024 | 112.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.52M
Minimum
Mar 19 2020
416.42M
Maximum
Jan 06 2022
150.04M
Average
150.40M
Median
Nov 09 2022
Enterprise Value Benchmarks
| Acasti Pharma Inc | 0.5379M |
| Aurinia Pharmaceuticals Inc | 424.68M |
| Edesa Biotech Inc | 11.48M |
| Lexaria Bioscience Corp | 45.09M |
| InMed Pharmaceuticals Inc | -5.135M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.213M |
| Total Expenses (Quarterly) | 7.424M |
| EPS Diluted (Quarterly) | -0.0222 |
| Earnings Yield | -36.14% |